Discontinued biological drugs in 2008
- 16 November 2009
- journal article
- Published by Informa Healthcare in Expert Opinion on Biological Therapy
- Vol. 9 (12) , 1453-1461
Abstract
This perspective is part of an ongoing series of articles that describe the drugs that were dropped from clinical development during the previous year. This paper focuses on those drugs that were discontinued in 2008. The drugs represent a diverse collection of compounds targeted at diseases including cancer, diabetes, infections, arthritis, HIV, restenosis, allergies, anaemia, osteoporosis, wound healing, and growth deficiency. No consistent theme is apparent that accounts for the diversity of discontinued drugs. Still, this diversity, coupled with the numbers of novel drugs that were approved in 2008 suggests a healthy ongoing drug development process.Keywords
This publication has 9 references indexed in Scilit:
- Placebo-Controlled Phase III Trial of Patient-Specific Immunotherapy With Mitumprotimut-T and Granulocyte-Macrophage Colony-Stimulating Factor After Rituximab in Patients With Follicular LymphomaJournal of Clinical Oncology, 2009
- Safety and efficacy of inhaled insulin (AERx® iDMS1) compared with subcutaneous insulin therapy in patients with Type 1 diabetes: 1‐year data from a randomized, parallel group trialDiabetic Medicine, 2009
- Pulmonary delivery of a GLP-1 receptor agonist, BMS-686117International Journal of Pharmaceutics, 2009
- PEGylation of somatropin (recombinant human growth hormone): Impact on its clearance in humansXenobiotica, 2008
- Phase I trial on the safety of topical rhVEGF on chronic neuropathic diabetic foot ulcersJournal of Wound Care, 2008
- Rheumatoid Arthritis: Diagnosis and ManagementThe American Journal of Medicine, 2007
- Inhaled insulin using AERx®insulin Diabetes Management System (AERx®iDMS)Expert Opinion on Investigational Drugs, 2007
- Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphomaBlood, 2007
- The Anti–Human Leukocyte Antigen-DR Monoclonal Antibody 1D09C3 Activates the Mitochondrial Cell Death Pathway and Exerts a Potent Antitumor Activity in Lymphoma-Bearing Nonobese Diabetic/Severe Combined Immunodeficient MiceCancer Research, 2006